ABSTRACT
Antagonistic properties of the strain Bacillus subtilis IB-54 with respect to dermatophyte fungi Trichophyton rubrum, T. mentagrophytes var. gypseum, Microsporum canis was studied. The studied strains of bacilli effectively inhibited growth and development of dermatophytes when were cultivated on the media containing different carbon sources. Experiments on laboratory animals showed that B. subtilis IB-54 displayed no virulence, toxicity, and toxigenicity and can be considered as perspective object for development of antimycotic drugs.
Subject(s)
Antibiosis , Bacillus subtilis/physiology , Microsporum/growth & development , Trichophyton/growth & development , Animals , Antifungal Agents , Bacillus subtilis/pathogenicity , Culture Media , MiceABSTRACT
The study demonstrated a possibility to detect specific anti-CMV antibody activity in intravenous preparations of immunoglobulins by qualitative immunoenzyme analysis using parallel-line method. Independently of production technology, specificity, and the activity level, the preparations had a dose-response curve that was parallel to that of a standard sample with five-point linearity at double-step dilution. This makes it possible to use the test system DS-ELISA-ANTI-CMV-G to detect anti-CMV antibody activity in ready-for-use preparations.
Subject(s)
Antibodies, Viral/analysis , Cytomegalovirus Infections/drug therapy , Cytomegalovirus/immunology , Immunoglobulins, Intravenous/pharmacology , Immunologic Factors/pharmacology , Cytomegalovirus/drug effects , Cytomegalovirus Infections/virology , Enzyme-Linked Immunosorbent Assay , HumansABSTRACT
New medicinal forms of immunobiological preparations--human lekocytic interferon and bactisporin--have been developed for local application in dentistry, surgery, gynecology. As the basis for these preparations, the pharmacopeial collagen solution has been used. The results obtained in this investigation indicate that the preparations are safe and possess wound-healing properties.
Subject(s)
Bacillus subtilis , Interferons/therapeutic use , Pharmaceutic Aids , Probiotics/therapeutic use , Wounds and Injuries/therapy , Animals , Antibiosis , Bacillus subtilis/physiology , Collagen , Cryopreservation , Drug Evaluation, Preclinical , Humans , Pharmaceutic Aids/chemistryABSTRACT
Pumala virus recombinant nucleocapsid protein was used for the early diagnosis of haemorrhagic fever with renal syndrome. Specific IgM in the sera of patients could be determined by the IEA technique as early as on days 2-3 from the onset of the disease. The diagnostic effectiveness of the test-system was 95% and its specificity was 98%.
Subject(s)
Hemorrhagic Fever with Renal Syndrome/diagnosis , Nucleocapsid/immunology , Puumala virus/immunology , Antibodies, Viral/blood , Escherichia coli/metabolism , Genetic Vectors , Hemorrhagic Fever with Renal Syndrome/blood , Humans , Immunoenzyme Techniques , Immunoglobulin M/blood , Nucleocapsid/genetics , Nucleocapsid Proteins , Recombinant Proteins/immunology , Sensitivity and Specificity , Serologic TestsSubject(s)
Communicable Disease Control/trends , Vaccination/trends , Bashkiria/epidemiology , Communicable Disease Control/statistics & numerical data , Communicable Diseases/epidemiology , Disease Outbreaks/prevention & control , Disease Outbreaks/statistics & numerical data , Humans , Incidence , Morbidity/trends , Vaccination/statistics & numerical dataABSTRACT
The production of virus-neutralizing antibodies in high titers has been found to occur in persons immunized with tissue-culture rabies vaccines, concentrated and non concentrated, intramuscularly in a dose of 1 ml in accordance with reduced immunization schedules.
Subject(s)
Immunization Schedule , Rabies Vaccines/immunology , Adolescent , Adult , Antibodies, Viral/analysis , Antibody Formation , Drug Evaluation , Humans , Middle Aged , Neutralization Tests , Rabies/prevention & control , Rabies Vaccines/administration & dosage , Rabies Vaccines/adverse effects , Rabies virus/immunology , Time FactorsABSTRACT
The results obtained in the study of the specific potency of rabies vaccine prepared from sheep brain tissue and inactivated by UV irradiation indicate that, even in the presence of the lowest immunogenicity index (0.5), 5-6 injections of the vaccine, made not daily, but at interval of 3 and 7 days, induced the production of antibodies in the titers not lower than those resulting from 14-20 daily injections of the same vaccine or Fermi vaccine. The preparation inactivated by UV irradiation should be introduced for therapy according to the shortened immunization schedule with intervals, taking into account the immunogenicity index.